PHARMARESOURCES (SHANGHAI) CO., LTD. PharmaResources (Shanghai) Co., Ltd. Stock
Equities
301230
CNE1000065Q9
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.87 CNY | +1.73% |
|
-2.81% | -8.18% |
| Apr. 25 | PharmaResources Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 24 | PharmaResources Co., Ltd. Proposes Final Cash Dividend for the Year 2023 | CI |
| Sales 2024 * | 852M 118M | Sales 2025 * | 1.12B 155M | Capitalization | 3.52B 486M |
|---|---|---|---|---|---|
| Net income 2024 * | 146M 20.16M | Net income 2025 * | 195M 26.93M | EV / Sales 2024 * | 4.13 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.14 x |
| P/E ratio 2024 * |
24.3
x | P/E ratio 2025 * |
18.2
x | Employees | 1,047 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 31.88% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.73% | ||
| 1 week | -2.81% | ||
| 1 month | -5.87% | ||
| 3 months | +15.86% | ||
| 6 months | -14.40% | ||
| Current year | -8.18% |
1 week
31.77
35.29
1 month
31.7742.00
Current year
21.1654.99
1 year
21.1657.50
3 years
21.1657.50
5 years
21.1657.50
10 years
21.1657.50
| Managers | Title | Age | Since |
|---|---|---|---|
Ping Chen
CEO | Chief Executive Officer | 66 | 07-12-13 |
Shi Cheng Li
DFI | Director of Finance/CFO | 47 | 14-07-31 |
Xiao Jing He
BRD | Director/Board Member | 38 | 09-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qi Dong You
BRD | Director/Board Member | 69 | 20-07-31 |
Zheng Fei
BRD | Director/Board Member | 51 | 13-05-31 |
Sheng Li Jiang
BRD | Director/Board Member | 53 | 07-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 32.87 | +1.73% | 2,287,940 |
| 24-05-30 | 32.31 | -0.58% | 1,888,533 |
| 24-05-29 | 32.5 | +0.03% | 2,211,560 |
| 24-05-28 | 32.49 | -5.55% | 4,032,978 |
| 24-05-27 | 34.4 | +1.71% | 3,285,738 |
End-of-day quote Shenzhen S.E., May 30, 2024
More quotes
PharmaResources Shanghai Co Ltd is a China-based company mainly engaged in the development and commercial production of new drugs. The Company's main businesses include drug discovery, process research and development and commercial manufacturing business. The drug discovery business includes medicinal chemistry, synthetic chemistry and pharmacokinetics. The process research and development business includes process chemistry and process development as well as bulk drug research. The commercial manufacturing business includes customized manufacturing of new drugs and the research and development, production and sales of proprietary generic drug products. The Company distributes its products to the United States, India and other countries.
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
32.87
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.18% | 486M | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- 301230 Stock
